Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at JPMorgan US All-Stars Conference (Virtual) Transcript

Sep 16, 2020 / 03:00PM GMT
Cory William Kasimov;Jean;Jacques BienaimÃ
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. I think we are live here now. So good morning or good afternoon. I guess even good evening to some of you. My name is Cory Kasimov, I'm a Senior Biotech Analyst at JPMorgan. And it's my pleasure to host this next session at the 11th Annual, but first time virtual, U.S. All stars Conference with BioMarin. And here from the company, we have J.J. Bienaimé, the Chairman and CEO; Hank Fuchs, President of Worldwide R&D; and Brian Mueller, the newly appointed CFO.

So in terms of structure, in just a minute, I'm going to turn things over to J.J. and Hank for some opening comments from management. Then I'll run through a bunch of my questions. But remember, you also have the ability to ask questions with a function on your webcast, so feel free to send those in throughout, and we'll work them into the conversation.

So with that, let me hand it over to J.J. and Hank for some opening comments to kick things off here.

-©,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot